Pricing Log in Create free account
Friday 6 November 2026 Export CRIS’s income statement to Excel — free account

Curis, Inc.

CRIS Healthcare Biotechnology

Curis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.4 million, down 13.4% from fiscal 2024.

Revenue
−66.0%
EPS
+70.4%
Free cash flow
−20.4%

Quarter to June 2026, against a year earlier

0.88 0.03 +3.53%
Market cap
$5.7M
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
4/9
Altman Z
−87.83
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.01
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — 1 — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 5.67
Revenue ttm 9.44
Net income ttm (21.15)
Free cash flow ttm (30.59)
Net debt Q (5.62)
Valuation
P/E 0.00
Forward P/E (0.03) (negative: loss-making)
Price / sales 0.20
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.40
Financial health
Current ratio Q 0.49 (below 1: weak)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q 22.65
Growth
Revenue growth Q −65.98% (below 0%: shrinking)
Operating income growth Q −20.47% (below 0%: shrinking)
EPS, this year −180.00% (below 0%: weak)
EPS, next year A +84.53% (at or above 15%: strong)
Revenue, next year A −2.04% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +6.87%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −0.3×, against a ten-year median of 4.8×; over the ten years it ranged from −4.7× in 2022 to 113× in 2021.
P/S against its own 10 years 1.14%
10-year low 10-year high
P/B against its own 10 years 1.73%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 56 20 5 6
Receivables 3 3 — —
Inventory — — — —
Other — — — —
61 26 7 7
2023 2024 2025 Q'26
Payables 3 3 6 5
ST’ Debt — — — —
Other 9 8 — —
22 19 14 14

Compound Annual Growth %

10y 5y 3y
Sales 1.83% (2.71%) (2.42%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (21.88%) (47.00%) (51.04%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −5.70 Actual −4.02

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −12.40 −9.80 Beat by 2.60
Q4 FY25 −11.80 −10.00 Beat by 1.80
Q1 FY26 −3.80 −25.00 Miss by 21.20
Q2 FY26 −5.70 −4.02 Beat by 1.68
Q3 FY26 −2.29 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (25.00) (4.02) — — —
’25 (25.00) (13.60) (9.80) 24.60 (11.60)
’24 (41.00) (40.60) (34.00) (25.00) (137.60)
’23 (48.00) (48.00) (42.60) (40.60) (179.20)
’22 (72.00) (68.00) (56.00) (48.00) (244.00)
’21 (44.00) (48.00) (48.00) (60.00) (200.00)
’20 (112.00) (68.00) (44.00) (44.00) (244.00)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 2 3 3 1 9
’24 2 3 3 3 11
’23 2 2 3 3 10
’22 2 2 3 3 10
’21 2 2 3 3 11
’20 3 2 3 3 11
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (9) (10) — — —
’25 (7) (8) (6) (6) (27)
’24 (13) (11) (6) (9) (40)
’23 (12) (8) (8) (10) (38)
’22 (17) (12) (13) (12) (54)
’21 (13) (7) (10) (8) (38)
’20 (9) (5) (6) (6) (26)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (9) (10) — — —
’25 (7) (8) (6) (6) (27)
’24 (13) (11) (6) (9) (40)
’23 (12) (8) (8) (10) (38)
’22 (17) (12) (13) (12) (55)
’21 (13) (7) (10) (8) (38)
’20 (9) (5) (6) (6) (26)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 8 10 10 10 11 11 10 10 11 9 9 +2.6% 9 9 29 +45.5%
Gross margin, % 94.70 94.99 94.60 94.97 95.07 94.99 97.47 97.88 99.10 99.52 99.52 +4.8 pt
EBT (60) (53) (33) (32) (30) (45) (57) (47) (43) (8) (21) (20.6%)
EBT margin, % (802.59) (538.66) (312.38) (321.28) (276.03) (426.67) (557.69) (473.04) (397.77) (80.29) 0.00 +722.3 pt
Net income (60) (53) (33) (32) (30) (45) (57) (47) (43) (8) (21) (20.6%)
Per share, $
Per share, $ Revenue 113.36 132.68 125.94 120.53 89.03 46.52 43.52 37.87 34.60 14.35 0.00 (20.5%)
Earnings (900.00) (720.00) (392.00) (388.00) (244.00) (200.00) (244.00) (179.20) (137.60) (11.60) (14.22) (38.3%)
Cash flow (539.32) (648.19) (363.10) (315.72) (211.50) (164.35) (232.71) (145.20) (125.48) (41.33) (14.32) (24.8%)
Capex (4.95) (2.52) (1.03) (0.49) (5.56) 0.00 (1.78) 0.00 0.00 0.00 0.00 n/m
Free cash flow (544.28) (650.71) (364.13) (316.22) (217.06) (164.35) (234.49) (145.20) (125.48) (41.33) (14.32) (24.9%)
Book value 440.75 321.62 (54.30) (408.57) 1,073.71 396.27 199.37 74.31 (19.02) 8.30 2.20 (35.7%)
Shares, m 0 0 0 0 0 0 0 0 0 1 1 +29.0%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 57.16 11.19 2.19 5.64 36.80 40.93 5.66 6.58 1.77 1.38 0.20 16.9
P/B 14.70 4.61 0.00 0.00 3.05 4.80 1.24 3.35 0.00 2.38 0.40 3.4
EV/Sales 53.89 9.30 3.27 9.83 21.33 30.16 (2.64) 1.08 0.05 0.97 (0.27) 12.7
EV/FCF (11.22) (1.90) (1.13) (3.75) (8.75) (8.39) 0.49 (0.28) (0.01) (0.33) 0.08 (3.5)
Cash, $m
Cash, $m Operating cash flow (36) (48) (30) (26) (26) (38) (54) (38) (40) (27) (31) (3.0%)
Capex 0 0 0 0 (1) — 0 — — — 0 +4.0%
Free cash flow (36) (49) (30) (26) (26) (38) (55) (38) (40) (27) (31) (3.1%)
Balance, $m
Balance, $m Working capital 35 50 15 18 163 109 82 39 7 (7) (7) n/m
Net debt (25) (19) 11 42 (168) (116) (86) (56) (20) (5) (6) (16.1%)
Shareholders’ equity 29 24 (4) (34) 131 91 47 20 (6) 5 5 (17.0%)
Returns, %
Returns, % ROA (79.11) (81.06) (58.61) (88.70) (24.98) (24.78) (41.80) (50.95) (73.20) (24.77) (87.76) +54.3 pt
ROIC (781.61) (585.03) (272.90) (189.43) 0.00 0.00 0.00 0.00 0.00 (890.43) 0.00 (108.8) pt
ROE (128.84) (200.22) (334.15) 167.37 (61.82) (41.05) (82.58) (143.19) (634.72) 2,829.10 455.35 +2,957.9 pt
People
People Employees 58 55 31 28 28 41 51 49 34 24 — (9.3%)
Revenue/emp, $m 0.13 0.18 0.34 0.36 0.39 0.26 0.20 0.20 0.32 0.39 — +13.1%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2025

Curis, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
APRE Aprea Therapeutics, Inc. $6.2M — (loss-making) — (loss-making) −98.40% (below 0%: shrinking) n/m −5.22% (below 0%: shrinking) 100.00% 0.00% Compare
AIM AIM ImmunoTech Inc. $6.1M — (loss-making) — (loss-making) +4.00% (above 0%: growing) n/m −167.46% (below 0%: shrinking) 80.77% (13,511.54%) Compare
EVGN Evogene Ltd. $6.0M — (loss-making) — (loss-making) −35.02% (below 0%: shrinking) n/m +17.72% (above 0%: growing) 40.63% (738.62%) Compare
CNSP CNS Pharmaceuticals, Inc. $5.9M — (loss-making) — — n/m +33.70% (above 0%: growing) 0.00% 0.00% Compare
XCUR Exicure, Inc. $5.8M — (loss-making) — (loss-making) −80.51% (below 0%: shrinking) n/m +65.38% (above 0%: growing) 100.00% 0.00% Compare
ORGS Orgenesis Inc. $5.7M — (loss-making) 1.0× +82.42% (above 0%: growing) n/m −317.93% (below 0%: shrinking) 2,780.73% (6,044.52%) Compare
CRIS Curis, Inc. $5.7M — (loss-making) — (loss-making) −65.98% (below 0%: shrinking) n/m −20.44% (below 0%: shrinking) 100.00% 0.00%
LGVN Longeveron Inc. $5.5M — (loss-making) — (loss-making) −9.18% (below 0%: shrinking) n/m −49.12% (below 0%: shrinking) 63.41% (2,150.17%) Compare
ACXP Acurx Pharmaceuticals, Inc. $5.3M — (loss-making) — — n/m −2.36% (below 0%: shrinking) — 0.00% Compare
Median of peers $5.8M — — −22.10% — −3.79% 80.77% (369.31%)

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 5 June 2026

Ownership

Directors and executive officers, together 5.78%
Entities affiliated with Nantahala Capital Partners Limited Partnership 9.99%
Entities affiliated with Thomas A. Satterfield, Jr. 9.99%
Stonepine Capital, LP 9.99%
Entities affiliated with Bleichroeder LP 9.99%
Pointillist Partners LLC 9.99%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Curis, Inc. (CRIS) Latest News

16 Oct

Impact 3 · · PR Newswire

5 Aug

Impact 3 ·

30 Jul

Impact 3 ·

27 Jul

Impact 4 ·

22 Jul

Impact 4 · · InvestorsHub
Impact 4 ·

29 Jun

Impact 3 · · clinicaltrialsarena.com

26 Jun

Impact 3 ·

2 Jun

Impact 3 · · The Motley Fool transcript

13 May

Impact 4 · · Moby
Impact 4 · · GuruFocus.com

12 May

Impact 3 · · PR Newswire

19 Mar

Impact 4 · · GuruFocus.com
Impact 4 · · Moby
Impact 4 · · The Motley Fool transcript
Impact 3 · · Associated Press Finance

10 Feb

Impact 4 · · Simply Wall St.ReutersReutersExec EdgeTechCrunchBenzingaBarchartBeInCrypto

11 Jan

Impact 4 ·

9 Jan

Impact 4 · · PR Newswire

7 Jan

Impact 4 ·

9 Dec

Impact 4 · · PR Newswire

28 Nov

Impact 4 · · Simply Wall St.

14 Nov

Impact 3 · · PR Newswire

13 Nov

Impact 3 · · Simply Wall St.

9 Nov

Impact 3 · · Simply Wall St.

7 Nov

Impact 4 · · GuruFocus.com transcript

6 Nov

Impact 4 · · PR Newswire
Impact 3 · · ZacksAssociated Press FinanceZacksZacksZacksZacksZacks
Impact 3 · · Associated Press Finance

8 Aug

Impact 3 · · Simply Wall St.
stockrow.com/CRIS · Data as of Dec 31, 2025 · For information only; not investment advice. · © 2026 stockrow.com